Bridgepoint Group (LON:BPT) Earns Buy Rating from Jefferies Financial Group

Bridgepoint Group (LON:BPT)‘s stock had its “buy” rating restated by research analysts at Jefferies Financial Group in a report issued on Thursday, October 8th, Digital Look reports. They currently have a GBX 485 price target on the stock. Jefferies Financial Group’s target price would indicate a potential upside of 22.17% from the stock’s current price.

Separately, Berenberg Bank reissued a “buy” rating and set a GBX 360 price target on shares of Bridgepoint Group in a research report on Friday, September 18th. Four investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Bridgepoint Group has an average rating of “Buy” and an average price target of GBX 413.75.

Bridgepoint Group Stock Performance

Shares of BPT traded up GBX 7 during mid-day trading on Thursday, hitting GBX 397. The stock had a trading volume of 89,917,438 shares, compared to its average volume of 7,950,192. The company has a market cap of £3.58 billion, a PE ratio of 132.33, a PEG ratio of 0.61 and a beta of 1.39. The company’s fifty day simple moving average is GBX 326.47 and its two-hundred day simple moving average is GBX 289.16. The company has a quick ratio of 3.60, a current ratio of 16.31 and a debt-to-equity ratio of 53.71. Bridgepoint Group has a fifty-two week low of GBX 212 and a fifty-two week high of GBX 416.20.

Bridgepoint Group Company Profile

Bridgepoint Group plc is a private equity and private credit firm specializing in middle market, small mid cap, small cap, growth capital, buyouts investments, syndicate debt, infrastructure, direct lending and credit opportunities in private credit investments. It prefers to invest in advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, testing inspection and certification, information services, consumer, digital brands, video games, wellbeing products, health care, pharma and MedTech outsourced services, pharma products, and MedTech Products sectors.